Healios Poised to Go into the Black with Sakigake-Designated MultiStem, Revs Up Universal Cell Biz

Healios CEO Tadahisa Kagimoto Tokyo-based biotech Healios looks to achieve the black ink in two to three years after the launch of its investigational off-the-shelf cell therapy product MultiStem, while accelerating its drive to eventually establish gene-edited universal donor iPSCs...read more